BioSpace News Archive

Pramana, Inc. and Techcyte have joined forces to deliver the first intelligent volumetric scanning and digital diagnostics solution for cytology, microbiology, and hematology applications.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).

Clarity Pharmaceuticals and PSI CRO AG have entered into an agreement and have commenced work towards Clarity’s Phase III diagnostic trial of SAR-bisPSMA in prostate cancer participants, CLARIFY 1.

Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Steven Vicik , PhD, as Chief Technical Officer (CTO).

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration has accepted for review ImmunityBio’s resubmission of its Biologics License Application for N-803, a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease, and considered it as a complete response to the FDA’s May 9, 2023 complete response letter.

Catawba Research, a leading clinical research organization with a goal to become the world’s most trusted CRO, is announcing changes to its executive leadership team.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023.

Sonoma Pharmaceuticals, Inc. today announced the pricing of its public offering of 8,500,000 shares of common stock at a price of $0.20 per share.

The extraordinary general meeting in Orexo AB on 26 October 2023 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be eight with no deputy board members.

elo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is pleased to announce that it has passed all requirements and received its Certificate of Accreditation of ISO 15189.